These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 20185312)

  • 1. Design, synthesis and evaluation of constrained tetrahydroimidazopyrimidine derivatives as antagonists of corticotropin-releasing factor type 1 receptor (CRF1R).
    Vrudhula VM; Dasgupta B; Pin SS; Burris KD; Balanda LA; Fung LK; Fiedler T; Browman KE; Taber MT; Zhang J; Macor JE; Dubowchik GM
    Bioorg Med Chem Lett; 2010 Mar; 20(6):1905-9. PubMed ID: 20185312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists.
    Huang CQ; Wilcoxen KM; Grigoriadis DE; McCarthy JR; Chen C
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3943-7. PubMed ID: 15225703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
    Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
    J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corticotropin-releasing hormone receptor antagonists: framework design and synthesis guided by ligand conformational studies.
    Hodge CN; Aldrich PE; Wasserman ZR; Fernandez CH; Nemeth GA; Arvanitis A; Cheeseman RS; Chorvat RJ; Ciganek E; Christos TE; Gilligan PJ; Krenitsky P; Scholfield E; Strucely P
    J Med Chem; 1999 Mar; 42(5):819-32. PubMed ID: 10072680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of benzoylpyrimidines as antagonists of the corticotropin-releasing factor-1 receptor.
    Webb TR; Moran T; Huang CQ; McCarthy JR; Grigoriadis DE; Chen C
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3869-73. PubMed ID: 15225687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and SAR of 2-dialkylamino-4-arylpyrimidines as potent and selective corticotropin-releasing factor(1) (CRF(1)) receptor antagonists.
    Huang CQ; Grigoriadis DE; Liu Z; McCarthy JR; Ramphal J; Webb T; Whitten JP; Xie MY; Chen C
    Bioorg Med Chem Lett; 2004 May; 14(9):2083-6. PubMed ID: 15080983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 6,7-Dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidines and their derivatives as novel corticotropin-releasing factor 1 receptor antagonists.
    Saito T; Obitsu T; Kondo T; Matsui T; Nagao Y; Kusumi K; Matsumura N; Ueno S; Kishi A; Katsumata S; Kagamiishi Y; Nakai H; Toda M
    Bioorg Med Chem; 2011 Sep; 19(18):5432-45. PubMed ID: 21865047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-Arylpyrimidines: novel CRF-1 receptor antagonists.
    Yoon T; De Lombaert S; Brodbeck R; Gulianello M; Krause JE; Hutchison A; Horvath RF; Ge P; Kehne J; Hoffman D; Chandrasekhar J; Doller D; Hodgetts KJ
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4486-90. PubMed ID: 18672365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An orally active corticotropin releasing factor 1 receptor antagonist from 8-aryl-1,3a,7,8-tetraaza-cyclopenta[a]indenes.
    Han X; Civiello R; Pin SS; Burris K; Balanda LA; Knipe J; Ren S; Fiedler T; Browman KE; Macci R; Taber MT; Zhang J; Dubowchik GM
    Bioorg Med Chem Lett; 2007 Apr; 17(7):2026-30. PubMed ID: 17258456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF₁) receptor antagonists.
    Saito T; Obitsu T; Minamoto C; Sugiura T; Matsumura N; Ueno S; Kishi A; Katsumata S; Nakai H; Toda M
    Bioorg Med Chem; 2011 Oct; 19(20):5955-66. PubMed ID: 21930387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility.
    Chen C; Wilcoxen KM; Huang CQ; McCarthy JR; Chen T; Grigoriadis DE
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3669-73. PubMed ID: 15203140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists.
    Chen C; Dagnino R; De Souza EB; Grigoriadis DE; Huang CQ; Kim KI; Liu Z; Moran T; Webb TR; Whitten JP; Xie YF; McCarthy JR
    J Med Chem; 1996 Oct; 39(22):4358-60. PubMed ID: 8893829
    [No Abstract]   [Full Text] [Related]  

  • 13. Rational design, synthesis, and structure-activity relationships of aryltriazoles as novel corticotropin-releasing factor-1 receptor antagonists.
    Lowe RF; Nelson J; Dang TN; Crowe PD; Pahuja A; McCarthy JR; Grigoriadis DE; Conlon P; Saunders J; Chen C; Szabo T; Chen TK; Bozigian H
    J Med Chem; 2005 Mar; 48(5):1540-9. PubMed ID: 15743196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclopenta[d]pyrimidines and dihydropyrrolo[2,3-d]pyrimidines as potent and selective corticotropin-releasing factor 1 receptor antagonists.
    Arban R; Benedetti R; Bonanomi G; Capelli AM; Castiglioni E; Contini S; Degiorgis F; Di Felice P; Donati D; Fazzolari E; Gentile G; Marchionni C; Marchioro C; Messina F; Micheli F; Oliosi B; Pavone F; Pasquarello A; Perini B; Rinaldi M; Sabbatini FM; Vitulli G; Zarantonello P; Di Fabio R; St-Denis Y
    ChemMedChem; 2007 Apr; 2(4):528-40. PubMed ID: 17335099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heteroaryl-substituted 4-(1H-pyrazol-1-yl)-5,6-dihydro-1H-pyrrolo[2,3-d]pyrimidine derivatives as potent and selective corticotropin-releasing factor receptor-1 antagonists.
    Sabbatini FM; Di Fabio R; St-Denis Y; Capelli AM; Castiglioni E; Contini S; Donati D; Fazzolari E; Gentile G; Micheli F; Pavone F; Rinaldi M; Pasquarello A; Zampori MG; Di Felice P; Zarantonello P; Arban R; Perini B; Vitulli G; Benedetti R; Oliosi B; Worby A
    ChemMedChem; 2008 Feb; 3(2):226-9. PubMed ID: 18000940
    [No Abstract]   [Full Text] [Related]  

  • 16. Discovery of pyrrolo[2,3-d]pyrimidin-4-ones as corticotropin-releasing factor 1 receptor antagonists with a carbonyl-based hydrogen bonding acceptor.
    Aso K; Kobayashi K; Mochizuki M; Kanzaki N; Sako Y; Yano T
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2365-71. PubMed ID: 21414781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of 1,2,3,7-tetrahydro-6h-purin-6-one and 3,7-dihydro-1h-purine-2,6-dione derivatives as corticotropin-releasing factor(1) receptor antagonists.
    Hartz RA; Nanda KK; Ingalls CL; Ahuja VT; Molski TF; Zhang G; Wong H; Peng Y; Kelley M; Lodge NJ; Zaczek R; Gilligan PJ; Trainor GL
    J Med Chem; 2004 Sep; 47(19):4741-54. PubMed ID: 15341489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, structure-activity relationships, and anxiolytic activity of 7-aryl-6,7-dihydroimidazoimidazole corticotropin-releasing factor 1 receptor antagonists.
    Han X; Michne JA; Pin SS; Burris KD; Balanda LA; Fung LK; Fiedler T; Browman KE; Taber MT; Zhang J; Dubowchik GM
    Bioorg Med Chem Lett; 2005 Sep; 15(17):3870-3. PubMed ID: 15990298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3-Aryl pyrazolo[4,3-d]pyrimidine derivatives: Nonpeptide CRF-1 antagonists.
    Yuan J; Gulianello M; De Lombaert S; Brodbeck R; Kieltyka A; Hodgetts KJ
    Bioorg Med Chem Lett; 2002 Aug; 12(16):2133-6. PubMed ID: 12127521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.
    Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Nakazato A; Kumagai T; Okubo T; Tomisawa K
    J Pharmacol Exp Ther; 1999 May; 289(2):926-35. PubMed ID: 10215672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.